Vaccine Info

COVID-19 Vaccines

Authored by
Last reviewed
May 21, 2022

COVID-19 Vaccines In 2022

The U.S. Food and Drug Administration (FDA) has Approved two COVID-19 vaccines and issued three Emergency Use Authorizations. The initial FDA Approval was for the Comirnaty Pfizer-BioNTech vaccine on Aug. 23, 2021, followed by Moderna's SpikeVax vaccine on Feb. 4, 2022.

Furthermore, the FDA continues to Authorize the Jcovden COVID-19 vaccine from Janssen - Johnson & Johnson but on May 5, 2022, limited the use to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate and to adults who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive an mRNA COVID-19 vaccine.

The U.S. CDC reported on May 21, 2022, that about 66.5% of the U.S. population had been 'fully vaccinated' with an Approve/Authorized COVID-19 vaccine. And about 46.5% of eligible people have been 'boosted' and are now 'optimally' or 'up to date' vaccinated.

Separately, the European Centre for Disease Prevention and Control recently reported that about 72.7% of Europeans had completed their primary vaccination course, while about 51.7% have been 'boosted.'

In Europe, the European Medicines Commission authorized five COVID-19 vaccines and is reviewing five other vaccines. Additionally, the Maryland-based Novavax's Nuvaxovid protein-based vaccine recently joined the WHO List of eleven COVID-19 vaccines. The WHO's COVID-19 vaccine tracker compiles detailed information about each COVID-19 vaccine candidate in development. Globally, over 100 COVID-19 vaccine candidates are undergoing clinical trials, reported GAVI.

COVID-19 Vaccine Booster Authorizations For 2022

The U.S. FDA authorized a second booster dose (5th vaccination) of either the three-dose primary series Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals on March 29, 2022. And eligible children can receive reduced booster dosages of the COVID-19 vaccine. However, when turning 12 years old, adolescents should receive the total adult dosage.

On March 24, 2022, the CDC stated that adults who are moderately or severely immunocompromised and received the 1-dose of the Janssen COVID-19 vaccine should get a second dose of either Pfizer-BioNTech or Moderna, plus an mRNA COVID-19 vaccine booster to stay up to date for a total of 3 doses.

COVID-19 Vaccine Effectiveness Against SARS-CoV-2 Virus Variants (Omicron and BA.2 sublineages) 

As of May 12, 2022, the U.S. NIH OpenData Portal presents a database of COVID-19 vaccine in vitro therapeutic activity against SARS-CoV-2 Omicron sublineages. And the CDC's NowCast monitors active variants on a local level in the U.S. Separately, the U.K's CoVariants provide an overview of SARS-CoV-2 variants and mutations, as does the WHO.

The CDC estimated mRNA vaccine effectiveness against reinfection leading to hospitalization during the Omicron-predominant period as of April 15, 2022, was approximately 35% after dose #2 and 68% after a booster 3rd dose.

COVID-19 Vaccinations With Adolescents 2022

The U.S. CDC's Advisory Committee on Immunization Practices meeting presentation slides published on May 19, 2022, include the following: COVID-19 vaccine effectiveness during Omicron for children and adolescents, by Ruth Link-Gelles, Ph.D., MPH; COVID-19 vaccine safety updates: Primary series in children ages 5–11 years, by Tom Shimabukuro, MD, MPH, MBA; Updates to the Evidence to Recommendation Framework: Pfizer-BioNTech COVID-19 booster in children aged 5-11 years, by Sara Oliver, MD, MSPH.

Monoclonal Antibody Treatments and COVID-19 Antivirals

Various anti-SARS-CoV-2 mAbs and COVID-19 antivirals (oral and IV) are U.S. FDA Authorized. And, the CDC says it is no longer necessary to delay COVID-19 vaccination following receipt of monoclonal antibodies or convalescent plasma.'


  • This CDC webpage displays rates of COVID-19 cases and related deaths by COVID-19 vaccination status.
  • The CDC recently clarified that 'COVID-19 vaccines and other vaccines may be coadministered on the same day.
  • The Vaccine Adverse Event Reporting System (VAERS) is a passive reporting system, meaning it relies on individuals to send in reports of their experiences. Anyone can submit a vaccine side effect report to VAERS, including parents and patients.
  • Search, text your zip code to 438829, or call 1-800-232-0233 to find COVID-19 vaccine locations near you in the USA.
  • Vaccine and medication discount information are published by

Clinical Trials

No clinical trials found